SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
Courtesy of Getty Images
Business
Money on the Move: Pfizer Backs Mystery Company, Teva/AbbVie Settle Opioid Suits
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
July 13, 2022
 · 
3 min read
 · 
Hannah Chudleigh
Courtesy of Smith Collection/Gado/Getty Images
Business
AbbVie Half Breaks Up with Alector on Alzheimer’s
In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
July 8, 2022
 · 
2 min read
 · 
Vanessa Doctor, RN
Courtesy of AbbVie, Inc.
Policy
AbbVie’s Tax Structure in Crosshairs of Senate Finance Committee Report
A Senate Finance Committee report shows the majority of AbbVie’s income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.
July 7, 2022
 · 
3 min read
 · 
Alex Keown
Deals
PwC Projects ‘Flurry of Deals’ Across Life Science Industry
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
June 24, 2022
 · 
3 min read
 · 
Mark Terry
Courtesy of Abbvie Inc.
Policy
AbbVie Redeems Priority Review Voucher for Rinvoq Approval
AbbVie has redeemed a Rare Pediatric Disease Priority Review Voucher for Rinvoq (upadactinib), following its FDA approval for adults with moderately to severely active ulcerative colitis in March.
June 23, 2022
 · 
3 min read
 · 
Mark Terry
SKYRIZI is the new option for psoriatic arthritis.
Drug Development
AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic
AbbVie filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for Qulipta for the preventative treatment of migraine.
June 22, 2022
 · 
3 min read
 · 
Alex Keown
Courtesy of Abbvie Inc.
Drug Development
AbbVie’s Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn’s Disease
The FDA’s decision is based on positive results from two induction and one maintenance clinical study of AbbVie’s Skyrizi for Crohn’s disease.
June 20, 2022
 · 
2 min read
 · 
Vanessa Doctor, RN
Drug Development
Clinical Catch-Up: AbbVie and Genmab, Intra-Cellular, Sanofi and GSK
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular’s bipolar depression candidate hits the endpoint in Phase III and more.
June 17, 2022
 · 
6 min read
 · 
Mark Terry
Tahi Ahmadi/both courtesy of Genmab
Drug Development
AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Genmab’s Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
June 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
April 21, 2023
 · 
9 min read
FDA
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
April 17, 2023
 · 
26 min read
Policy
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn’s Disease
April 17, 2023
 · 
21 min read
Business
AbbVie to Host First-Quarter 2023 Earnings Conference Call
April 4, 2023
 · 
1 min read
BioMidwest
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
March 29, 2023
 · 
5 min read
Drug Development
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
March 23, 2023
 · 
18 min read
Drug Development
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
March 23, 2023
 · 
14 min read
BioMidwest
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
March 22, 2023
 · 
4 min read
BioMidwest
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
March 18, 2023
 · 
13 min read
BioMidwest
AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema
March 15, 2023
 · 
4 min read
Load More